Becton, Dickinson and Company (NYSE:BDX) Posts Earnings Results, Beats Expectations By $0.20 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20, RTT News reports. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the prior year, the firm earned $2.86 EPS. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. Becton, Dickinson and Company updated its FY24 guidance to $12.95-13.15 EPS.

Becton, Dickinson and Company Trading Down 2.4 %

NYSE BDX opened at $234.68 on Friday. The company has a current ratio of 1.41, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The firm’s fifty day simple moving average is $238.45 and its 200-day simple moving average is $240.53. The company has a market capitalization of $67.80 billion, a PE ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Upgrades and Downgrades

Separately, Barclays increased their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.